Key Points
- Jeremy Hayden sold 3,150 shares of Sight Sciences at an average price of $8.01 on Nov. 12, netting $25,231.50 and trimming his holding by 1.21% to 256,590 shares (≈$2.06M).
- Shares traded at $7.11 (up 0.9%) with a market cap of $375.9M and a 52-week range of $2.03–$8.06; the company reported a quarterly EPS of −$0.81 on $12.54M revenue and posts negative ROE and net margins.
- Analysts have an average rating of "Hold" with a consensus price target of $5.17, and institutional investors own about 55.51% of the stock, with several funds recently increasing or initiating positions.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Jeremy Hayden sold 3,150 shares of the firm's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $8.01, for a total transaction of $25,231.50. Following the completion of the sale, the insider directly owned 256,590 shares of the company's stock, valued at approximately $2,055,285.90. The trade was a 1.21% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Sight Sciences Trading Up 0.9%
Shares of NASDAQ:SGHT traded up $0.06 during trading hours on Friday, hitting $7.11. 308,466 shares of the company's stock traded hands, compared to its average volume of 313,502. The firm has a market capitalization of $375.91 million, a P/E ratio of -7.90 and a beta of 2.47. The business has a fifty day moving average price of $4.35 and a 200-day moving average price of $3.95. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $8.06. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share (EPS) for the quarter. The business had revenue of $12.54 million for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%. Equities analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.
Hedge Funds Weigh In On Sight Sciences
Large investors have recently bought and sold shares of the business. KCK LTD. bought a new stake in Sight Sciences during the 2nd quarter valued at $18,069,000. Long Focus Capital Management LLC raised its position in shares of Sight Sciences by 39.7% in the 1st quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company's stock worth $7,504,000 after acquiring an additional 887,876 shares in the last quarter. Americana Partners LLC purchased a new stake in shares of Sight Sciences during the 2nd quarter worth $3,568,000. Acadian Asset Management LLC boosted its position in Sight Sciences by 127.7% during the first quarter. Acadian Asset Management LLC now owns 432,541 shares of the company's stock valued at $1,033,000 after purchasing an additional 242,559 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Sight Sciences by 5.7% in the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock valued at $6,559,000 after purchasing an additional 102,609 shares during the last quarter. Institutional investors own 55.51% of the company's stock.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Citigroup dropped their target price on shares of Sight Sciences from $4.50 to $4.00 and set a "neutral" rating on the stock in a research note on Tuesday, October 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research report on Thursday, August 28th. Piper Sandler lifted their price target on shares of Sight Sciences from $4.00 to $5.00 and gave the company a "neutral" rating in a research note on Friday, November 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Sight Sciences in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $5.17.
Check Out Our Latest Stock Report on Sight Sciences
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
